

**MINUTES**  
**CONTROLLED SUBSTANCES ADVISORY COMMITTEE MEETING**  
**April 15, 2025 | 1 P.M.**  
**Room 474, 4<sup>th</sup> Floor**  
**160 E 300 S Salt Lake City UT**

**CONVENED: 1 :02 P.M.**

**ADJOURNED: 2:17 P.M.**

**DOPL STAFF PRESENT:**

**Bureau Manager:** Jim Garfield  
**Board Secretary:** Tina Marshall  
**CSD Policy Manager:** Connie Kitchens  
**CSD Administrator:** Jeff Henrie

**Pharmacy Program Specialist:** Maddy Holt

**COMMITTEE MEMBERS PRESENT:**

**Chair:** Stacey Bank, MD  
Benjamin Murie, MD  
Julie P. Balk, DNP, APRN  
Christopher Sheard, Pharm D  
Amberly Johnson, Pharm D  
Jennifer McNair, BS  
Erik D. Christensen, MD

Craig William Davis, MD  
Kate Miyagi, ND  
Katherine Carlson, MD  
Maury Giles, Public Member  
Megan Martin, Substance Abuse Addiction  
Expert

**COMMITTEE MEMBERS NOT PRESENT:**

Erica Baiden, MD  
Jimmy Higgs

Marc Mathis, JD

**GUESTS ATTENDED ELECTRONICALLY:**

Kelly Whittle-Utah Bureau of Forensic Services  
*Note: Others may have attended, but were not identified.*

**ADMINISTRATIVE BUSINESS:**

**CALL MEETING TO ORDER**

**Dr. Bank called the meeting to order at 1:02 P.M.**

**OATH OF OFFICE – STACEY BANK (Audio 00:05:50)**

Stacey Bank was sworn in as a member of the Committee.

**OATH OF OFFICE – MEGAN MARTIN (Audio 00:06:27)**

Megan Martin was sworn in as a member of the Committee.

**OATH OF OFFICE – BENJAMIN MURIE (Audio 00:06:51)**

Benjamin Murie was sworn in as a member of the Committee.

**APPROVE April 16, 2024, MEETING MINUTES (Audio 00:07:41)**

**Dr. Sheard made a motion to approve the minutes, with corrections as discussed.**

**Dr. Carlson seconded the motion.**

**The Committee motion passed unanimously.**

**APPROVE August 20, 2024, MEETING MINUTES** (*Audio 00:11:24*)

**Dr. Balk made a motion to approve the minutes, with corrections as discussed.**

**Dr. Sheard seconded the motion.**

**The Committee motion passed unanimously.**

**APPROVE September 18, 2024, MEETING MINUTES** (*Audio 00:18:38*)

**Dr. Miyagi made a motion to approve the minutes as written.**

**Dr. Sheard seconded the motion.**

**The Committee motion passed unanimously.**

**DISCUSSION ITEMS:**

**Legislative Update** (*Audio 00:29:04*)

Mr. Garfield provided a Legislative update on a few bills that passed during the 2025 Legislative session.

Mr. Garfield explained that HB173 added tianeptine and phenibut to Schedule I of the controlled substances list. The Committee had included tianeptine and phenibut in the 2024 Legislative letter as drugs to discuss. With tianeptine and phenibut becoming scheduled during the 2025 Legislative session, the Committee no longer needs to discuss.

Mr. Garfield explained that HB87 created a criminal offense for trafficking of fentanyl or fentanyl-related substances.

Mr. Garfield explained that SB120 created an exemption for veterinarians in the Utah controlled substance act for gabapentin.

Mr. Garfield explained that HB357 moves enforcement of advertising and payment requirements related to medical cannabis to the Division of Professional Licensing from the Department of Health and Human Services.

**Fenfluramine** (*Audio 00:49:00*)

Mr. Garfield explained that the Division has received inquiries about fenfluramine. Fenfluramine was descheduled at the Federal level by the DEA in 2023. Fenfluramine is still a scheduled drug in the State of Utah.

Mr. Garfield asked the Committee if they would like to discuss if they would like to recommend that fenfluramine be descheduled or leave it as a scheduled drug.

The Committee discussed what fenfluramine is used for and the reasons for it being scheduled.

**Dr. Balk made a motion to keep fenfluramine as a scheduled drug.**

**Dr. Carlson seconded the motion.**

**The Committee motion passed unanimously.**

## **REPORTS:**

### **Law Enforcement – Jimmy Higgs (Audio 00:57:19)**

Mr. Higgs was unable to attend the meeting.

### **State Crime Lab – Jennifer McNair (Audio 00:57:22)**

Ms. McNair explained that the state lab tests seized drugs to identify what they are. Ms. McNair described the top ten most frequently submitted drugs to the lab in 2024.

### **Utah Poison Control – Amberly Johnson (Audio 01:00:03)**

Dr. Johnson explained that in quarter four of 2024 and quarter one of 2025 there were approximately 928 reported case of use and misuse. The top substance reported to Utah poison control during that time period were amphetamines at 28%.

### **Medical Examiner – Benjamin Murie (Audio 01:03:20)**

Dr. Murie explained that their epidemiology team has found that fentanyl has surpassed methamphetamines in the most common substance found in overdoses.

### **Health Department & Hospitals – Stacey Bank (Audio 01:04:04)**

Dr. Bank explained that the epidemiology team at the state medical examiner's office received ongoing funding from the Legislature. The correctional health services received funding from the opioid settlement money for programs in the prison system.

### **CSD – Jeff Henrie (Audio 01:04:51)**

Mr. Henrie explained the numbers of several substances that were submitted to the drug threat analysis group for the years 2021 through 2024. Mr. Henrie also explained the tracking of the same substances from 2010 through 2024 in graph form.


Mr. Henrie informed the Committee that the CSD is in the process of updating the nation drug code tables.

Ms. Kitchens explained that a new website has been created for controlled substance providers to access the information that they need in one place. The website is [cstoolkit.utah.gov](https://cstoolkit.utah.gov).

**NEXT SCHEDULED MEETING: August 19, 2025**

**ADJOURNED: Meeting adjourned at 2:17 P.M.**

*Note: These minutes are not intended to be a verbatim transcript but are intended to record the significant features of the business conducted in this meeting. Discussed items are not necessarily shown in the chronological order they occurred.*

(ss)   
Chairperson  
Controlled Substances Advisory Committee

08/19/2025  
Date

(ss)   
Bureau Manager

08/20/2025  
Date